Based on 1 analysts giving stock ratings to Dermata Therapeutics Inc in the past month.
In the current month, DRMA has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. DRMA average Analyst price target in the last month is 4.000.
Based on analysts' estimates, DRMA EPS is projected to reach -0.460 in FY2026Q4, following reported EPS of -0.551 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
The market expectation was USD -0.55, while Dermata Therapeutics IncDRMA's earnings per share (EPS) for the previous quarter was USD -0.74. EPS for the next quarter is expected at USD -0.46.